Abstract
A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (-03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 ± 130; A2, 700 ± 107; B, 520 ± 80 pg/ml, analysis of variance p > 0.5) and on Day 9 (A1, 1051 ±144; A2, 1140 ± 155; B, 840 ± 124 pg/ml, p > 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (± 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 ± 0.9; A2, 4.0 ± 0.7; B, 4.5 ± 0.9, p > 0.05; Day 9: total A1, 6.7 ± 0.9; A2, 6.9 ± 0.8; B, 6.9 ± 0.9, p > 0.05) in all three cycles were also similar. There was no significant difference in the day of hCG administration (A1, 9.1 ± 0.2; A2, 9.0 ± 0.1; B, 9.2 ± 0.2) or the total number of ampules of hMG utilized on Day 9 (A1, 1.1 ± 0.4; A2, 0.6 ± 0.2; B, 0.8 ±0.2). This study extends our previous observations in ovulatory women that ovarian response to hMG induction of superovulation is similar in successive cycles and demonstrates in vivo consistency of human ovarian response to different lots of Pergonal±
| Original language | English (US) |
|---|---|
| Pages (from-to) | 135-139 |
| Number of pages | 5 |
| Journal | Gynecological Endocrinology |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 1 1992 |
Fingerprint
Keywords
- Bioequivalence
- Follicles
- Human Menopausal Gonadotropin
- Oocytes
- Ovulation Induction
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
- Obstetrics and Gynecology
Cite this
Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin. / Diamond, M. P.; Polar, M. L.; Blanchette, M.; Mazure, C. M.; Dechemey, A. H.; Lunenfeld, B.
In: Gynecological Endocrinology, Vol. 6, No. 2, 01.01.1992, p. 135-139.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin
AU - Diamond, M. P.
AU - Polar, M. L.
AU - Blanchette, M.
AU - Mazure, C. M.
AU - Dechemey, A. H.
AU - Lunenfeld, B.
PY - 1992/1/1
Y1 - 1992/1/1
N2 - A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (-03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 ± 130; A2, 700 ± 107; B, 520 ± 80 pg/ml, analysis of variance p > 0.5) and on Day 9 (A1, 1051 ±144; A2, 1140 ± 155; B, 840 ± 124 pg/ml, p > 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (± 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 ± 0.9; A2, 4.0 ± 0.7; B, 4.5 ± 0.9, p > 0.05; Day 9: total A1, 6.7 ± 0.9; A2, 6.9 ± 0.8; B, 6.9 ± 0.9, p > 0.05) in all three cycles were also similar. There was no significant difference in the day of hCG administration (A1, 9.1 ± 0.2; A2, 9.0 ± 0.1; B, 9.2 ± 0.2) or the total number of ampules of hMG utilized on Day 9 (A1, 1.1 ± 0.4; A2, 0.6 ± 0.2; B, 0.8 ±0.2). This study extends our previous observations in ovulatory women that ovarian response to hMG induction of superovulation is similar in successive cycles and demonstrates in vivo consistency of human ovarian response to different lots of Pergonal±
AB - A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (-03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 ± 130; A2, 700 ± 107; B, 520 ± 80 pg/ml, analysis of variance p > 0.5) and on Day 9 (A1, 1051 ±144; A2, 1140 ± 155; B, 840 ± 124 pg/ml, p > 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (± 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 ± 0.9; A2, 4.0 ± 0.7; B, 4.5 ± 0.9, p > 0.05; Day 9: total A1, 6.7 ± 0.9; A2, 6.9 ± 0.8; B, 6.9 ± 0.9, p > 0.05) in all three cycles were also similar. There was no significant difference in the day of hCG administration (A1, 9.1 ± 0.2; A2, 9.0 ± 0.1; B, 9.2 ± 0.2) or the total number of ampules of hMG utilized on Day 9 (A1, 1.1 ± 0.4; A2, 0.6 ± 0.2; B, 0.8 ±0.2). This study extends our previous observations in ovulatory women that ovarian response to hMG induction of superovulation is similar in successive cycles and demonstrates in vivo consistency of human ovarian response to different lots of Pergonal±
KW - Bioequivalence
KW - Follicles
KW - Human Menopausal Gonadotropin
KW - Oocytes
KW - Ovulation Induction
UR - http://www.scopus.com/inward/record.url?scp=0026773634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026773634&partnerID=8YFLogxK
U2 - 10.3109/09513599209046397
DO - 10.3109/09513599209046397
M3 - Article
C2 - 1502931
AN - SCOPUS:0026773634
VL - 6
SP - 135
EP - 139
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
SN - 0951-3590
IS - 2
ER -